
|Videos|October 26, 2022
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
Author(s)Urology Times staff
Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Advertisement
Rana McKay, MD, discusses the evolving treatment paradigm in the second-line setting for advanced renal cell carcinoma now that immunotherapy has revolutionized the first-line approach. McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5











